| |
Monday, October 17, 2022 | 11am ET / 8am PT Given the wide array of post transcriptional and post translational regulatory processes that govern cellular dynamics, additional omics types are needed to capture a more comprehensive understanding of the molecular landscape of a tumor. Register now to learn more.
|
|
Today's Big NewsOct 13, 2022 |
| By Nick Paul Taylor GSK was hiding a strong hand in the high-stakes respiratory syncytial virus vaccine game. Having kept its phase 3 results under wraps, the Big Pharma has now released data from the trial—and revealed itself to be a genuine challenger for a market targeted by Pfizer, Johnson & Johnson and Moderna. |
|
|
|
By James Waldron Relmada Therapeutics’ lead asset has flunked a phase 3 trial in major depressive disorder, plunging the biotech’s stock down 77%. |
By Nick Paul Taylor The Odyssey Therapeutics story is progressing quickly. Ten months after disclosing a $218 million series A, the Gary Glick-helmed biotech is back with another mega round as it prepares to push candidates into IND-enabling studies next year. |
By Max Bayer Otonomy had hoped that its hearing loss med could revive clinical aspirations, but phase 2 data of the higher dose groups disappointed. The company reported the dosing levels did not meaningfully improve hearing from baseline compared to placebo. |
By Gabrielle Masson Rates of septic shock, a serious complication of sepsis, are on the rise. With only antibiotics and symptomatic treatment available, biotech Inotrem hopes its investigational treatment could be the first mechanism-based therapy to treat the life-threatening condition. |
By Helen Floersh Researchers have identified an enzyme that when inhibited, slowed viral replication and improved outcomes in mice infected with a wide range of viruses. |
By Joseph Keenan VigiLanz, which specializes in clinical software surveillance, debuted its latest tool to identify a greater number of eligible candidates for clinical trial enrollment. |
By Joseph Keenan Regulatory review company Advarra surpassed a milestone by expanding its gene therapy network to more than 1,000 research sites. |
By Ben Adams How do you solve a problem like Elon Musk? Well, when it comes to his weight, there seems to be a simple answer: Novo Nordisk’s Wegovy. |
By Andrea Park Most neurostimulation devices can be manually adjusted by users and their caregivers to customize treatments for chronic pain, epilepsy, stroke recovery and more, but an implant newly approved by the FDA outsources some of those tweaks to artificial intelligence. |
By Fraiser Kansteiner Late last week, Bayer’s Egypt unit unveiled a three-year strategy to crank out 60% to 70% of its over-the-counter consumer drugs there locally. Just a few days later, GSK confirmed via email that it’s shuttering commercial operations in Kenya next year as it pivots to a third-party distribution model for its drugs and vaccines. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about the trend of retail giants getting involved primary care. Also under discussion is our special report spotlighting the important contributions made by people of color across health systems, physicians' offices, health tech and insurance companies. |
|
|---|
|
|
|
Scaling biotechs are at a unique intersection of capital, opportunity and flexibility. And real estate is key to driving business forward. Get answers to six key questions to ensure you have the space and solutions to grow where and when you need to. Learn more.
|
|
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| Whitepaper Supporting your product development programme through experience, expertise, and efficiency. Sponsored by: Almac Pharma Services |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
